The disclosure relates to an electrosurgical device and methods of use thereof. More specifically, the disclosure relates to an electrosurgical probe and methods of using the probe to prevent tumor seeding.
Tumor seeding may be prevented when withdrawing an energy delivery probe through a path that includes at least some bone tissue, by withdrawing the probe through the path while delivering energy in a bipolar manner to heat tissue surrounding the probe to a temperature sufficient to result in thermal coagulation necrosis of cells. The probe may be withdrawn incrementally or continuously. Examples of when such a method is useful include withdrawing a probe after ablating tissue or performing a biopsy.
In one broad aspect, embodiments of the present invention comprise a method of withdrawing a probe through a tissue via a path that traverses at least some bone tissue, the method including withdrawing the probe through the path, and at least partially concurrently delivering energy in a bipolar manner from the probe to heat a layer of tissue surrounding the probe to a temperature sufficient for thermal coagulation necrosis of cells.
As a feature of this broad aspect, some embodiments further comprise withdrawing the probe incrementally and measuring a temperature of the layer of tissue surrounding at least a portion of the path surrounding the probe prior to each incremental withdrawal to determine if the temperature is sufficient for thermal coagulation necrosis of cells.
In another broad aspect, embodiments of the present invention include a method of withdrawing a probe having an active tip through a tissue via a path, the method comprising: withdrawing the probe through the path in increments each having an increment length; and, for each incremental withdrawal, delivering energy from the active tip of the probe to heat a layer of tissue surrounding the probe to a temperature sufficient for thermal coagulation necrosis of cells to thereby define a coagulation volume, wherein the increment length is less than or equal to a length of the coagulation volume.
In yet another broad aspect, embodiments of the present invention include a method of withdrawing a probe having an active tip through a tissue via a path, the method comprising: continuously withdrawing the probe through the path while concurrently delivering energy from the active tip to heat a layer of tissue surrounding the probe; measuring a tissue parameter to confirm thermal coagulation necrosis of cells adjacent the probe; and adjusting a level of energy being delivered or a rate of probe withdrawal based on the measured tissue parameter.
Another broad aspect of an embodiment of the invention is directed towards a system including: an electrosurgical generator; at least one bipolar probe operable to be coupled to the electrosurgical generator, the at least one bipolar probe including at least one active electrode, at least one return electrode and at least one temperature sensor; and at least one introducer defining a lumen sized to receive the at least one bipolar probe; the generator being operable to: deliver electrical energy in a radiofrequency range; automatically detect at least one probe parameter of a probe coupled thereto; receive a measurement of at least one tissue parameter; substantially continuously adjust an energy delivery parameter in response to the at least one probe parameter and the at least one tissue parameter, the energy delivery parameter being selected from the group consisting of voltage and impedance; and provide an indication to a user when the at least one tissue parameter reaches a pre-determined threshold.
Certain embodiments of the present invention comprise a method of treating a tumor within a target tissue using an energy delivery probe, the method comprising the steps of (a) at least partially concurrently delivering energy from the energy delivery probe to ablate at least a part of the tumor and cooling the energy delivery probe with a probe cooling system; and (b) withdrawing the delivery probe incrementally through an entry/exit path and at least partially concurrently delivering energy from the energy delivery probe, with the probe cooling system turned off, to heat a layer of tissue surrounding and adjacent the probe to a temperature sufficient for thermal coagulation necrosis of cells in the layer of tissue.
As features of this aspect: in some embodiments, the energy delivery probe is a bipolar probe having fixed geometry electrodes; the method includes using an introducer (having markings for indicating a probe insertion distance) to advance the energy delivery probe to a tissue ablation treatment site; and step (b) further comprises coupling the energy delivery probe and introducer, and withdrawing the energy delivery probe and introducer by an incremental withdrawal distance equivalent to about a length of an active tip of the energy delivery probe.
Alternative embodiments of the present invention comprise a method of treating a tumor at least partially within a bone tissue using an energy delivery probe, the method comprising the steps of (a) at least partially concurrently delivering energy from the energy delivery probe to ablate at least a part of the tumor located within the bone tissue and cooling the energy delivery probe with a probe cooling system; and (b) withdrawing the delivery probe through an entry/exit path and at least partially concurrently delivering energy from the energy delivery probe, with the probe cooling system turned off, to heat a layer of tissue surrounding and adjacent the probe to a temperature sufficient for thermal coagulation necrosis of cells in the layer of tissue.
In further embodiments of the present invention, a method of treating a tumor at least partially within a bone tissue using an energy delivery probe is described. The method comprises the steps of (a) delivering energy from the energy delivery probe to ablate the tumor at least partially within the bone tissue; and (b) withdrawing the delivery probe incrementally through an entry/exit path and at least partially concurrently delivering energy from the energy delivery probe to heat a layer of tissue surrounding and adjacent the probe to a temperature sufficient for thermal coagulation necrosis of cells in the layer of tissue.
In yet further embodiments of the present invention, a method of withdrawing an energy delivery probe through a tissue via an entry/exit path that traverses at least some bone tissue is described. The method comprises withdrawing the probe through the path that includes at least some bone tissue and at least partially concurrently delivering energy in a bipolar manner from the probe to heat a layer of tissue surrounding the probe to a temperature sufficient for thermal coagulation necrosis of cells.
In order that the invention may be readily understood, embodiments of the invention are illustrated by way of examples in the accompanying drawings, in which:
Radiofrequency-based devices are often used to ablate in soft tissues such as the liver in order to treat tumors located therein. Biopsy devices are often used to take samples from tumorous or possibly tumorous tissue. Following the procedure, a process of coagulating the tissue surrounding the insertion path of the device, sometimes referred to as track burning, may be used to reduce the chances of tumor seeding. However, ablating in bone tissue using an electrosurgical device for delivering electrical energy, and track burning when withdrawing the device, poses unique challenges due, for example, to the electrical properties of bone. The present inventors have discovered and reduced to practice various embodiments of a unique electrosurgical probe and methods of using the probe to coagulate the tissue surrounding the insertion path of the device.
In particular, the inventors have discovered that an electrosurgical probe structured to confine delivery of energy at its active tip (i.e. without requiring energy to flow to a grounding pad on the surface of a body) is particularly useful in a method for preventing tumor seeding when withdrawing the energy delivery probe through a path, the path including at least some bone tissue. The method comprises withdrawing the probe through the path while delivering energy in a bipolar manner from the probe to heat tissue surrounding the probe to a temperature sufficient to result in thermal coagulation necrosis of cells. The inventors have also discovered that, contrary to the delivery of energy during lesion formation, it is unpredictably advantageous to deliver energy without cooling (i.e. to disengage the cooling or turn it off) when using such a probe to coagulate a layer of tissue surrounding the probe's insertion and withdrawal path.
As an additional advantage of an embodiment of the present invention, a bipolar probe that has the active and return electrodes longitudinally displaced from each other on the same shaft (i.e. distal and proximal electrodes) will typically have a temperature distribution in the ablation zone with higher temperatures in relative proximity to the probe (especially when the cooling is turned off), when compared to monopolar devices that require an external grounding pad, whereby a single bipolar probe is operable to coagulate a thinner layer of tissue than a monopolar device.
In some embodiments, a bipolar probe having an active and a return electrode on a single shaft has a constant distance between the electrodes, referred to as a fixed or non-variable geometry, which provides for a relatively short and more predictable electrical flow pathway between electrodes than a system having a monopolar probe and a grounding pad. In a monopolar system, the pathway between the energy delivery electrode and grounding pad changes as the probe is withdrawn and, therefore, the pathway taken by the electrical current (and the types of tissue crossed) varies to a greater extent in monopolar procedures. Consequently, when track burning with a monopolar system, the variation in the different types of tissue crossed make it difficult to predictably/reliably achieve a consistent coagulation depth through the track (path of insertion/withdrawal). A single bipolar probe has more consistent energy flow because the electrode size, geometry, and distance of separation are typically fixed, and therefore the pathway through which the electrical current travels is better defined.
As a yet further advantage, in some embodiments, the probe includes a means for temperature monitoring which is particularly advantageous when used, for example, in tissue that hinders the predictability of lesioning, such as electrically insulative tissue including bone. A temperature-based algorithm for withdrawing a probe can include withdrawing the probe incrementally and measuring the tissue temperature prior to each incremental withdrawal to determine if the temperature is high enough for thermal coagulation necrosis of cells.
For some embodiments having distal and proximal electrodes, the temperature sensor (e.g. a thermocouple) is at or near the distal electrode. When energy is delivered by the probe when stationary, a volume of tissue around the electrodes and between the electrodes is heated to comprise a heated volume of tissue, with the space between the electrodes typically reaching the highest temperature. When the probe is withdrawn in a continuous manner, the tissue is first heated in the region of the heated volume around the proximal electrode, then in the region of the heated volume between the electrodes, and subsequently in the region of the heated volume around the distal electrode, whereby tissue surrounding the probe is typically hottest around the probe's distal electrode. When the probe is withdrawn in overlapping increments, the distal electrode starts each increment at a location that was heated during the previous increment. Temperature monitoring may aid in providing an effective amount of energy (sufficient but not excessive) to create a layer of coagulated cells adjacent the probe (sometimes referred to herein as simply “the path”). Temperature monitoring is beneficial for track burning through challenging anatomies, such as for example, when the entry/exit path goes through bone tissue or a transition zone from one type of tissue to another. Temperature monitoring is further beneficial for embodiments in which cooling is turned off during track burning to help prevent excess tissue coagulation.
In some such embodiments, the distal electrode is at the distal tip of the probe and the temperature sensor (e.g. a thermometer) is at the distal end of the distal electrode where the temperature is typically highest during withdrawal of the probe when track burning. This allows for more accurate control of the probe temperature at its hottest portion.
Thus, in one broad aspect of the present invention, a method is described for preventing tumor seeding when withdrawing a single energy delivery probe through a path, the path including at least some bone tissue. The method comprises withdrawing the probe through the path while delivering energy in a bipolar manner from the probe to heat tissue surrounding the path to a temperature sufficient to result in thermal coagulation necrosis of cells.
Furthermore, in another broad aspect of the present invention, a method for ablating a tumor in tissue and preventing tumor seeding when withdrawing the energy delivery probe is described. The method comprises delivering energy to ablate the target site with a probe cooling system turned on or activated and withdrawing the probe incrementally through the entry/exit path (the track) with the cooling system turned off or deactivated, while at least partially concurrently (i.e. overlapping in duration) delivering energy to heat tissue surrounding the probe to a temperature sufficient to result in thermal coagulation necrosis of cells adjacent the probe. In some such procedures, the tumor is at least partially in bone tissue. In some alternative embodiments, the procedure is performed by withdrawing the probe continuously, i.e. not incrementally. In other alternative embodiments, the procedure is performed without cooling the probe during ablation.
As used herein, the term “bipolar probe” is understood to mean a probe having an active tip including at least two electrically isolated electrodes whereby energy may be delivered between those electrodes in a manner which substantially confines the energy to an area substantially surrounding the active tip and obviates the need for a grounding pad or return electrode on the surface of a patient's body, thereby avoiding a flow of electrical energy through the patient's body from the active tip to such a grounding pad. Although the term “bipolar” is used herein, it should be understood to include other forms of energy delivery whereby energy flows substantially between electrodes located on the probe rather than to a grounding pad on the surface of the patient's body.
With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of certain embodiments of the present invention only. Prior to explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
The inner conductor 30 and the outer conductor 50 are electrically conductive along their length. In one example as shown in
The inner elongate conductor 30 as shown in
In one example, the proximal electrode 52 is a return electrode and the cooling fluid cools the proximal electrode 52 prior to reaching and cooling the distal electrode 32, which is the active electrode. This may provide a more uniform lesion to be produced when RF energy is supplied to the probe 100.
In one embodiment the active tip 70 may have a length (L1+L2+L3) that ranges from about 5 mm to about 40 mm. In one example, the length of the distal electrode 32 (L1), the exposed inner insulator 40 (L2), and the proximal electrode 52 (L3) may vary in about a 2:1:2 ratio. In other embodiments the ratio may be in about a 1:1:1 configuration. Alternate embodiments are possible as well. In other embodiments, the lengths L1, L2 and L3 may have a different ratio. In another example, the L1:L2:L3 ratio is about 7:6:7.
In another embodiment, the inner and outer conductors 30, 50 may only extend along a portion of the probe 100. In one specific example, as shown in
In this example, as shown in
Additionally, a temperature sensor 80 may be positioned at a location along the probe 100 as shown in
In some embodiments, a second temperature sensor is proximate to proximal electrode 52 and is in communication with a controller for the energy supply for providing additional information. Such an embodiment could be used with a generator capable of monitoring two temperature sensors at one time. Alternatively, a generator capable of monitoring only one temperature at a time could be used if an external device swapped between the two (or more) temperature sensors. Further details regarding the structure and use of some probe embodiments that may be used in the method of the present invention may be found in PCT application PCT/CA2011/050203, filed Apr. 15, 2011, and hereby incorporated by reference in its entirely.
When the lesion is completed, the probe cooling system is turned off i.e. the flow of cooling fluid is stopped. Probe 100 is withdrawn with energy still being supplied to the active electrode. Because the cooling system is turned off, tissue close to the probe heats faster than it would with the probe cooling system turned on. Consequently, as the probe is withdrawn it coagulates tissue closer to the probe than it would with cooling, as represented by track burn 120 of
In
One embodiment of a two-stage treatment as described above is a method of treating a tumor within a target tissue using an energy delivery probe 100 comprising the steps of: (a) at least partially concurrently delivering energy from the energy delivery probe 100 to ablate at least a part of the tumor and cooling the energy delivery probe with a probe cooling system; and (b) withdrawing the delivery probe 100 incrementally through an entry/exit path and at least partially concurrently delivering energy from the energy delivery probe 100, with the probe cooling system turned off, to heat a layer of tissue surrounding and adjacent the entry/exit path to a temperature sufficient for thermal coagulation necrosis of cells in the layer of tissue.
Another embodiment of the above described treatment procedure includes cooled ablation of a target site located at least partially within bone tissue followed by uncooled probe retraction, where the withdrawal is typically substantially continuous, i.e. not incremental. For example, a method of treating a tumor at least partially within a bone tissue using an energy delivery probe may comprise the steps of: (a) at least partially concurrently delivering energy from the energy delivery probe to ablate at least a part of the tumor at least partially within the bone tissue and cooling the energy delivery probe with a probe cooling system; and (b) withdrawing the delivery probe through an entry/exit path and at least partially concurrently delivering energy from the energy delivery probe, with the probe cooling system turned off, to heat a layer of tissue surrounding and adjacent the probe to a temperature sufficient for thermal coagulation necrosis of cells in the layer of tissue.
A still further embodiment or application of such a treatment procedure does not include delivering a cooling fluid during the ablation portion of the procedure. Typically, such embodiments include ablation of a target site at least partially within bone tissue, followed by probe retraction or withdrawal along with incremental track burning. An example of such an embodiment is a method of treating a tumor at least partially within a bone tissue using an energy delivery probe comprising the steps of: (a) delivering energy from the energy delivery probe to ablate the tumor at least partially within the bone tissue; and (b) withdrawing the delivery probe incrementally through an entry/exit path and at least partially concurrently delivering energy from the energy delivery probe to heat a layer of tissue surrounding and adjacent the probe to a temperature sufficient for thermal coagulation necrosis of cells in the layer of tissue.
The first step of
In some embodiments, represented by
The flowchart of
The first step of
In some embodiments represented by
The flowchart of
Alternative embodiments of track burning include using feedback based on monitoring the impedance (instead of temperature). Such embodiments comprise incrementally withdrawing the probe when the impedance increases beyond a certain threshold (mid-range impedance). A relatively low impedance level indicates tissue is not coagulated, mid-range impedance level indicates a track has been burned, and a high-range impedance level indicates the probe is out of the patient's body and the procedure should be stopped.
Probe 100 may be used to treat a region within a patient's body comprising tissue with varying composition, including soft tissues and hard tissues such as bone.
In some such applications, a method of track burning along a path including at least some bone tissue is used. The method includes using a bipolar probe with electrodes spaced apart on one shaft to provide a heat flow pattern in which the heat flows substantially proximate the probe shaft. Some embodiments include withdrawing the probe in incremental withdrawals and measuring the temperature before each incremental withdrawal to check for an adequate temperature for cell coagulation. Some embodiments of this method also include track burning with the probe cooling system turned off. Some specific embodiments include the use of a distal tip heat sensor, such as heat sensor 80 of
In one specific embodiment, a method of withdrawing an energy delivery probe 100 through tissue via an entry/exit path that traverses at least some bone tissue, includes withdrawing the probe 100 through the path and at least partially concurrently delivering energy in a bipolar manner from the probe 100 to heat tissue surrounding the entry/exit path to a temperature sufficient for thermal coagulation necrosis of cells. In some such embodiments, at least a portion of the entry/exit path is surrounded by and adjacent to bone tissue. In some embodiments, the entry/exit path traverses a tissue transition zone from one type of tissue to another type of tissue.
Some embodiments include using an introducer needle assembly for track burning, the introducer needle assembly including markings. One such embodiment is for a method using a bipolar probe with fixed geometry electrodes, the method including withdrawing the probe in short incremental withdrawals that result in overlapping coagulation volumes. When the probe is being withdrawn in increments, the temperature of the tissue surrounding the distal electrode normally very hot as it has previously been heated during the previous increment. Accordingly, this embodiment includes measuring the temperature at the distal electrode before each incremental withdrawal to check for an adequate temperature for cell coagulation while avoiding an excess temperature that would result in more tissue being coagulated than necessary. Some examples of this embodiment include the probe being withdrawn in incremental withdrawals of a distance that is approximately equal to or less than the length of the probe's active tip. To facilitate withdrawing the probe a specific desired distance, an introducer needle assembly with visible markings may be used whereby a user can visualize how far the introducer has been moved relative to the surface of the patient's skin. In the example of
Another characteristic of active tips is that, in general, if a shorter active tip is powered at the same level as a longer active tip, it achieves a higher temperature because, with the longer active tip, the heat dissipates into a larger volume of tissue. In the example of
In general, a procedure for preventing tumor seeding when withdrawing a single energy delivery probe through a path including at least some bone tissue comprises: withdrawing the probe through the path while delivering energy in a bipolar manner from the probe to heat tissue surrounding the path to a temperature sufficient to result in thermal coagulation necrosis of cells.
Furthermore, in alternate embodiments, a procedure for ablating a tumor in tissue and preventing tumor seeding when withdrawing the energy delivery probe can be performed by delivering energy to ablate the target site with a probe cooling system turned on and withdrawing the delivery device incrementally (for example, with the cooling system turned off) through the entry/exit path (the track), while at least partially concurrently (i.e. overlapping in duration) delivering energy to heat tissue surrounding the track to a temperature sufficient to result in thermal coagulation necrosis of cells. In some such procedures the tumor is at least partially in bone tissue. In some alternative embodiments, the procedure is performed by withdrawing the probe substantially continuously. In other alternative embodiments, the procedure is performed without cooling the probe during ablation.
The embodiments of the invention described above are intended to be exemplary only. The scope of the invention is therefore intended to be limited solely by the scope of the appended claims.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.
The present application is a continuation of U.S. application Ser. No. 15/879,572, filed Jan. 25, 2018; which is a continuation of U.S. application Ser. No. 14/195,972 filed Mar. 4, 2014; which claims the benefit of U.S. provisional application No. 61/774,213 filed Mar. 7, 2013; all of which are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3224436 | Massena | Dec 1965 | A |
3447161 | Weikel | Jun 1969 | A |
4532924 | Auth | Aug 1985 | A |
4674499 | Pao | Jun 1987 | A |
4849596 | Riordan | Jul 1989 | A |
4946460 | Merry | Aug 1990 | A |
5100388 | Behl et al. | Mar 1992 | A |
5261399 | Klatz | Nov 1993 | A |
5300068 | Rosar | Apr 1994 | A |
5300069 | Hunsberger | Apr 1994 | A |
5417713 | Cohen | May 1995 | A |
5462552 | Kiester | Oct 1995 | A |
5607389 | Edwards et al. | Mar 1997 | A |
5766167 | Eggers | Jun 1998 | A |
5797905 | Fleischman et al. | Aug 1998 | A |
5807395 | Mulier | Sep 1998 | A |
5843086 | Huyser et al. | Dec 1998 | A |
5935123 | Edwards et al. | Aug 1999 | A |
5947964 | Eggers et al. | Sep 1999 | A |
6066139 | Ryan | May 2000 | A |
6106524 | Eggers et al. | Aug 2000 | A |
6129726 | Edwards et al. | Oct 2000 | A |
6190378 | Jarvinen | Feb 2001 | B1 |
6261242 | Roberts et al. | Jul 2001 | B1 |
6293943 | Panescu et al. | Sep 2001 | B1 |
6306132 | Moorman | Oct 2001 | B1 |
6355033 | Moorman | Mar 2002 | B1 |
6398782 | Pecor | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6468268 | Abboud | Oct 2002 | B1 |
6524308 | Muller et al. | Feb 2003 | B1 |
6558379 | Batchelor | May 2003 | B1 |
6562033 | Shah et al. | May 2003 | B2 |
6592530 | Farhadi | Jul 2003 | B1 |
6634363 | Danek | Oct 2003 | B1 |
6770070 | Balbierz | Aug 2004 | B1 |
6845264 | Skladnev et al. | Jan 2005 | B1 |
6858025 | Maurice | Feb 2005 | B2 |
6881214 | Cosman et al. | Apr 2005 | B2 |
7108696 | Daniel et al. | Sep 2006 | B2 |
7160292 | Moorman et al. | Jan 2007 | B2 |
7160296 | Pearson et al. | Jan 2007 | B2 |
7216001 | Hacker et al. | May 2007 | B2 |
RE40388 | Gines | Jun 2008 | E |
7393350 | Maurice | Jul 2008 | B2 |
7435250 | Francischelli | Oct 2008 | B2 |
7824398 | Woloszko et al. | Nov 2010 | B2 |
7824404 | Godara et al. | Nov 2010 | B2 |
8167878 | VanDusseldorp | May 2012 | B2 |
8473067 | Hastings et al. | Jun 2013 | B2 |
8512335 | Cheng et al. | Aug 2013 | B2 |
8591507 | Kramer et al. | Nov 2013 | B2 |
8667674 | Buysse | Mar 2014 | B2 |
8709087 | Cragg | Apr 2014 | B2 |
8740895 | Mayse | Jun 2014 | B2 |
8936594 | Wolf et al. | Jan 2015 | B2 |
8936631 | Nguyen et al. | Jan 2015 | B2 |
9173700 | Godara | Nov 2015 | B2 |
9241760 | Godara | Jan 2016 | B2 |
9675408 | Godara et al. | Jun 2017 | B2 |
9788889 | Godara et al. | Oct 2017 | B2 |
9877707 | Godara et al. | Jan 2018 | B2 |
10105175 | Godara et al. | Oct 2018 | B2 |
10441339 | Lee et al. | Oct 2019 | B2 |
10448990 | Godara et al. | Oct 2019 | B2 |
10729490 | Godara et al. | Aug 2020 | B2 |
10918363 | Godara et al. | Feb 2021 | B2 |
20010014804 | Goble | Aug 2001 | A1 |
20010023348 | Ashley | Sep 2001 | A1 |
20010025177 | Woloszko | Sep 2001 | A1 |
20020022835 | Lee | Feb 2002 | A1 |
20020077627 | Johnson et al. | Jun 2002 | A1 |
20020115995 | Lesh | Aug 2002 | A1 |
20030040743 | Cosman et al. | Feb 2003 | A1 |
20030045870 | Madsen | Mar 2003 | A1 |
20030083655 | Van Wyk | May 2003 | A1 |
20030088245 | Woloszko et al. | May 2003 | A1 |
20030093007 | Wood | May 2003 | A1 |
20030097079 | Garcia | May 2003 | A1 |
20030109802 | Laeseke | Jun 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030148247 | Sicurelli, Jr. et al. | Aug 2003 | A1 |
20030149407 | DiResta | Aug 2003 | A1 |
20030171744 | Leung | Sep 2003 | A1 |
20030176816 | Maguire | Sep 2003 | A1 |
20030181963 | Pellegrino et al. | Sep 2003 | A1 |
20030212394 | Pearson | Nov 2003 | A1 |
20030212395 | Woloszko et al. | Nov 2003 | A1 |
20040015075 | Kimchy et al. | Jan 2004 | A1 |
20040030333 | Goble | Feb 2004 | A1 |
20040059328 | Daniel et al. | Mar 2004 | A1 |
20040127963 | Uchida | Jul 2004 | A1 |
20040167517 | Desinger et al. | Aug 2004 | A1 |
20040181219 | Goble | Sep 2004 | A1 |
20040193152 | Sutton et al. | Sep 2004 | A1 |
20050010205 | Hovda et al. | Jan 2005 | A1 |
20050027235 | Knudsen et al. | Feb 2005 | A1 |
20050038422 | Maurice | Feb 2005 | A1 |
20050070894 | McClurken | Mar 2005 | A1 |
20050119650 | Sanders et al. | Jun 2005 | A1 |
20050126563 | van der Burg et al. | Jun 2005 | A1 |
20050177209 | Leung | Aug 2005 | A1 |
20050177210 | Leung | Aug 2005 | A1 |
20050192564 | Cosman et al. | Sep 2005 | A1 |
20060064101 | Arramon | Mar 2006 | A1 |
20060111706 | Truckai et al. | May 2006 | A1 |
20060150986 | Roue et al. | Jul 2006 | A1 |
20060178666 | Cosman | Aug 2006 | A1 |
20060217705 | Godara | Sep 2006 | A1 |
20070016185 | Tullis et al. | Jan 2007 | A1 |
20070027449 | Godara et al. | Feb 2007 | A1 |
20070073282 | McGaffigan et al. | Mar 2007 | A1 |
20070123824 | Kaveckis | May 2007 | A1 |
20070129715 | Eggers | Jun 2007 | A1 |
20070179497 | Eggers | Aug 2007 | A1 |
20070198006 | Prakash et al. | Aug 2007 | A1 |
20070203551 | Cronin | Aug 2007 | A1 |
20070260237 | Sutton et al. | Nov 2007 | A1 |
20070265617 | Falkenstein | Nov 2007 | A1 |
20080004615 | Woloszko et al. | Jan 2008 | A1 |
20080015561 | Abboud | Jan 2008 | A1 |
20080021447 | Davison et al. | Jan 2008 | A1 |
20080021465 | Shadduck et al. | Jan 2008 | A1 |
20080033418 | Nields et al. | Feb 2008 | A1 |
20080051777 | Haemmerich | Feb 2008 | A1 |
20080065062 | Leung | Mar 2008 | A1 |
20080071270 | Desinger et al. | Mar 2008 | A1 |
20080077128 | Woloszko | Mar 2008 | A1 |
20080097424 | Wizeman | Apr 2008 | A1 |
20080097429 | McClurken | Apr 2008 | A1 |
20080103504 | Schmitz et al. | May 2008 | A1 |
20080172117 | Skubitz | Jul 2008 | A1 |
20080195112 | Liu et al. | Aug 2008 | A1 |
20080249350 | Marchitto | Oct 2008 | A1 |
20080255571 | Truckai et al. | Oct 2008 | A1 |
20080294155 | Cronin | Nov 2008 | A1 |
20080300587 | Anderson | Dec 2008 | A1 |
20090005775 | Jones | Jan 2009 | A1 |
20090012525 | Buehlmann et al. | Jan 2009 | A1 |
20090024124 | Lefler | Jan 2009 | A1 |
20090043301 | Jarrard | Feb 2009 | A1 |
20090054962 | Lefler | Feb 2009 | A1 |
20090069807 | Eggers | Mar 2009 | A1 |
20090118727 | Pearson | May 2009 | A1 |
20090156981 | Fay et al. | Jun 2009 | A1 |
20090204060 | Desinger | Aug 2009 | A1 |
20090264879 | McClurken | Oct 2009 | A1 |
20090312806 | Sherman et al. | Dec 2009 | A1 |
20090326527 | Ocel | Dec 2009 | A1 |
20100010480 | Mehta | Jan 2010 | A1 |
20100016854 | Carmel | Jan 2010 | A1 |
20100049190 | Long | Feb 2010 | A1 |
20100125269 | Emmons | May 2010 | A1 |
20100152725 | Pearson | Jun 2010 | A1 |
20100160922 | Liu et al. | Jun 2010 | A1 |
20100204687 | Abboud | Aug 2010 | A1 |
20100211058 | Winterbottom et al. | Aug 2010 | A1 |
20100286695 | Hannani et al. | Nov 2010 | A1 |
20100298622 | Vance et al. | Nov 2010 | A1 |
20100331883 | Schmitz | Dec 2010 | A1 |
20110022041 | Ingle et al. | Jan 2011 | A1 |
20110077451 | Marchitto | Mar 2011 | A1 |
20110077646 | Dahla | Mar 2011 | A1 |
20110118720 | Turner | May 2011 | A1 |
20110152855 | Mayse | Jun 2011 | A1 |
20110166518 | Nguyen | Jul 2011 | A1 |
20110301450 | Hue et al. | Dec 2011 | A1 |
20110319880 | Prakash | Dec 2011 | A1 |
20120016174 | De Taboada et al. | Jan 2012 | A1 |
20120029420 | Rittman, III | Feb 2012 | A1 |
20120172858 | Harrison | Jul 2012 | A1 |
20120209257 | van der Weide et al. | Aug 2012 | A1 |
20120215221 | Woloszko | Aug 2012 | A1 |
20120239049 | Truckai et al. | Sep 2012 | A1 |
20120265186 | Burger et al. | Oct 2012 | A1 |
20120296340 | Roue et al. | Nov 2012 | A1 |
20130012937 | Mulier et al. | Jan 2013 | A1 |
20130012940 | Desinger | Jan 2013 | A1 |
20130041369 | Godara | Feb 2013 | A1 |
20130060244 | Godara et al. | Mar 2013 | A1 |
20130085488 | Brannan | Apr 2013 | A1 |
20130226271 | Ferree | Aug 2013 | A1 |
20130253518 | Mitchell et al. | Sep 2013 | A1 |
20130296647 | Mayse | Nov 2013 | A1 |
20130324996 | Pellegrino et al. | Dec 2013 | A1 |
20130331835 | Leung | Dec 2013 | A1 |
20140081260 | Cosman | Mar 2014 | A1 |
20140128861 | Leung | May 2014 | A1 |
20140257265 | Godara | Sep 2014 | A1 |
20140303619 | Pappone | Oct 2014 | A1 |
20150374432 | Godara et al. | Dec 2015 | A1 |
20160045256 | Godara et al. | Feb 2016 | A1 |
20160113704 | Godara et al. | Apr 2016 | A1 |
20170119461 | Godara et al. | May 2017 | A1 |
20170135742 | Lee et al. | May 2017 | A1 |
20170245920 | Godara et al. | Aug 2017 | A1 |
20180042665 | Godara et al. | Feb 2018 | A1 |
20180146957 | Godara et al. | May 2018 | A1 |
20180153604 | Ayvazyan et al. | Jun 2018 | A1 |
20190343574 | Lee et al. | Nov 2019 | A1 |
20200046417 | Godara et al. | Feb 2020 | A1 |
20200330152 | Godara et al. | Oct 2020 | A1 |
Number | Date | Country |
---|---|---|
101132743 | Feb 2008 | CN |
101325919 | Dec 2008 | CN |
3756522 | Mar 2006 | JP |
2007113866 | Oct 2007 | WO |
Entry |
---|
International Search Report and Written Opinion for PCT/US2016/061557 dated Feb. 16, 2017. |
Supplementary European Search Report dated Jun. 18, 2019 of corresponding European Application No. 16866893.7. |
Office Action and Translation dated Apr. 30, 2020 from corresponding Chinese Application No. 201680066459.9. |
International Report on Patentability for Application: PCT/CA2011/050203 dated Oct. 30, 2012. |
International Search Report for Application: PCT/CA2011/050203 dated Jul. 14, 2011. |
European Search Report for EP11774249.4 dated Mar. 30, 2017. |
European Office Action for EP11774249.4 dated Apr. 11, 2017. |
Non-Final Office Action for U.S. Appl. No. 13/643,310, dated Dec. 15, 2014. |
Restriction Requirement for U.S. Appl. No. 13/643,310 dated Sep. 25, 2014. |
Non-Final Office Action for U.S. Appl. No. 13/660,353. |
Restriction Requirement for U.S. Appl. No. 13/660,353. |
Final Office Action for U.S. Appl. No. 13/660,353. |
Groenemeyer, Dietrich H.W et al. Image-guided Percutaneous Thermal Ablation of Bone Tumours. Academic Radiology, vol. 9, No. 4, Apr. 2002. |
Goh, Pyt. Radiofrequency ablation of lung tumours. Biomedical Imaging and Intervention Journal, vol. 2, No. 3: e39, 2006. |
AngioDynamics Incorporated Rita 1500X User's Guide and Service Manual Revision 03. |
Non-Final Office Action for U.S. Appl. No. 10/274,074 dated Mar. 23, 2005. |
Final Office Action for U.S. Appl. No. 10/274,074 dated Oct. 14, 2005. |
Non-Final Office Action for U.S. Appl. No. 10/274,074 dated Aug. 3, 2006. |
Final Office Action for U.S. Appl. No. 10/274,074 dated Mar. 22, 2007. |
Non-Final Office Action for U.S. Appl. No. 10/274,074 dated Aug. 3, 2007. |
Final Office Action for U.S. Appl. No. 10/274,074 dated Feb. 14, 2008. |
Final Office Action for U.S. Appl. No. 10/274,074 dated May 5, 2008. |
Non-Final Office Action for U.S. Appl. No. 10/274,074 dated Jul. 25, 2008. |
Number | Date | Country | |
---|---|---|---|
20210145416 A1 | May 2021 | US |
Number | Date | Country | |
---|---|---|---|
61774213 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15879572 | Jan 2018 | US |
Child | 17161202 | US | |
Parent | 14195972 | Mar 2014 | US |
Child | 15879572 | US |